CD5 and B-cell chronic lymphocytic leukemia: Although no significant changes of the percentage of CD19+CD5+ (leukemic cells) over the total CD19+ cells (B-cells) were observed in the BM and in the blood of treated mice versus controls, a significant reduction of the BM/blood ratio of CLL cells was apparent (Figure 2C).